School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Frank Keller

  • Department of Pediatrics
    Professor
  • fkeller@emory.edu
  • Children's Healthcare of Atlanta Provider Profile
  • Aflac Cancer & Blood Disorders Center
    Pediatrics
    2015 Uppergate Drive
Head shot of Frank Keller

Academic Appointment

  • Associate Professor of Pediatrics, Emory University
  • Associate Professor, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Emory University School of Medicine

Education

Degrees

  • BA from University of North Carolina at Asheville
  • MD from University of North Carolina at Chapel Hill

Research

Focus

  • Clinical research focusing on childhood/adolescent Hodgkin Disease, attempting to define novel methods to further reduce therapy, and attendant toxicity, for subjects with low-risk Hodgkin disease. Translational research, developing preliminary trials of Wolinella asparaginase, a novel asparaginase with potential efficacy and reduced toxicity in the treatment of childhood acute lymphoblastic leukemia.

Publications

  • Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.
    Pediatr Blood Cancer Page(s): e31856
    06/14/2025 Authors: Belsky JA; Renfro LA; Keller FG; Hodgson DC; Punnett A; McCarten K; Cho SY; Wu Y; Kelly KM; Castellino SM
  • Uniting for Change: The GLOW Initiative and Its Impact on Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Pediatr Blood Cancer Volume: 72 Page(s): e31699
    06/01/2025 Authors: Fridlyand DM; Keller F
  • Alternative mRNA splicing in anthracycline-induced cardiomyopathy - a COG-ALTE03N1 report.
    Cardiooncology Volume: 11 Page(s): 47
    05/17/2025 Authors: Singh P; Crossman DK; Cheng C; Trainor PJ; Sharafeldin N; Wang X; Zhou L; Hageman L; Armenian SH; Balis FM
  • Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma.
    JCO Oncol Pract Volume: 21 Page(s): 526 - 534
    04/01/2025 Authors: Heneghan MB; Parsons SK; Keller FG; Renfro LA; Pei Q; Rodday AM; Wu Y; Punnett A; Belsky JA; Henderson TO
  • Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.
    JAMA Oncol Volume: 11 Page(s): 340 - 342
    03/01/2025 Authors: Hoppe BS; Milgrom SA; Renfro LA; Wu Y; Schwartz CL; Constine LS; McCarten KM; Kelly KM; Hodgson D; Castellino SM
  • Pyrites: A Scalp Mass.
    J Pediatr Hematol Oncol Volume: 47 Page(s): 50 - 51
    01/01/2025 Authors: Sereyleak B; Lyvannak S; Bunpaov T; Sotherak H; Camitta B; Keller F
  • Pyrites: A Cervical Mass.
    J Pediatr Hematol Oncol Volume: 46 Page(s): 390 - 391
    10/01/2024 Authors: Lyvannak S; Sereyleak B; Keller FG; Jarzembowski J; Camitta B
  • Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study.
    J Clin Oncol Volume: 42 Page(s): 3330 - 3338
    10/01/2024 Authors: Williams AM; Rodday AM; Pei Q; Henderson TO; Keller FG; Punnett A; Kelly KM; Castellino SM; Parsons SK
  • Pyrites: Leukocytosis.
    J Pediatr Hematol Oncol Volume: 46 Page(s): 388 - 389
    10/01/2024 Authors: Phauk C; Nhip A; Lyvannak S; Sereyleak B; Keller FG; Jarzembowski J; Camitta B
  • Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma.
    Clin Cancer Res Volume: 30 Page(s): 3273 - 3281
    08/01/2024 Authors: Zhang Z; Zhang D; Guo W; Fenton K; Narayanan S; Jain S; Jiang J; Castellino SM; Kelly KM; Cole PD
  • Bartonella henselae Infection and Lymphadenopathy in a Patient With T Cell Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol Volume: 46 Page(s): e241 - e243
    04/01/2024 Authors: Sadanand A; Patel P; Riedesel E; Berkowitz F; Keller FG
  • Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
    J Patient Rep Outcomes Volume: 7 Page(s): 113
    11/10/2023 Authors: Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
  • Current directions in the treatment of classical Hodgkin lymphoma.
    EJHaem Volume: 4 Page(s): 908 - 911
    11/01/2023 Authors: Keller FG; Kahl B; Friedberg JW
  • Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.
    J Am Heart Assoc Volume: 12 Page(s): e029954
    10/03/2023 Authors: Singh P; Shah DA; Jouni M; Cejas RB; Crossman DK; Magdy T; Qiu S; Wang X; Zhou L; Sharafeldin N
  • Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy.
    Sci Rep Volume: 13 Page(s): 12683
    08/01/2023 Authors: Singh P; Zhou L; Shah DA; Cejas RB; Crossman DK; Jouni M; Magdy T; Wang X; Sharafeldin N; Hageman L
  • Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
    Int J Radiat Oncol Biol Phys Volume: 116 Page(s): 1025 - 1030
    08/01/2023 Authors: Hoppe BS; McCarten KM; Pei Q; Kessel S; Alazraki A; Mhlanga JC; Lai HA; Eutsler E; Hodgson DC; Roberts KB
  • 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
    Hematol Oncol Volume: 41 Suppl 2 Page(s): 69
    06/01/2023 Authors: Casey D; McCarten K; Pei Q; Milgrom S; Belsky J; Cho S; Keller F; Punnett A; Hoppe B; Kelly K
  • Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A COG-ALTE03N1 Report.
    JACC CardioOncol Volume: 5 Page(s): 392 - 401
    06/01/2023 Authors: Singh P; Crossman DK; Zhou L; Wang X; Sharafeldin N; Hageman L; Blanco JG; Burridge PW; Armenian SH; Balis FM
  • A single-center retrospective review of pediatric cases of progressive transformation of germinal centers.
    Pediatr Blood Cancer Volume: 70 Page(s): e30283
    06/01/2023 Authors: Sadanand A; Aljudi A; Bergsagel DJ; Keller FG
  • Pyrites: An Abdominal Mass.
    J Pediatr Hematol Oncol Volume: 45 Page(s): 103 - 104
    03/01/2023 Authors: Lyvannak S; Sereyleak B; Farrilend P; Thy V; Keller FG; Jarzembowski JA; Camitta B
  • Characteristics and outcomes of pediatric oncology patients at risk for guardians declining transfusion of blood components.
    Cancer Rep (Hoboken) Volume: 6 Page(s): e1665
    01/01/2023 Authors: Stevenson J; DeGroote NP; Keller F; Brock KE; Bergsagel DJ; Miller TP; Cornwell P; Fasano R; Chonat S; Castellino SM
  • Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation Rescues Marrow Failure From Acute Leukemia Therapy in a Patient With Previously Undiagnosed Ligase IV Syndrome.
    J Pediatr Hematol Oncol Volume: 45 Page(s): e139 - e141
    01/01/2023 Authors: Fridlyand DM; Chandrakasan S; Aljudi A; Aumann WK; Westfall E; Kirwan B; Bryson EW; Keller FG; Arnold SD; Hong AL
  • Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
    N Engl J Med Volume: 387 Page(s): 1649 - 1660
    11/03/2022 Authors: Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H
  • ALLIANCE A151804: ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNERELATED ADVERSE EVENTS
    Volume: 10 Page(s): A1289 - A1289
    11/01/2022 Authors: Kozono D; Zemla T; Dib E; Watson M; Wen Y; Keller F; Kirkwood J; Lyman G; Naidoo J; Mulhern B
  • Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
    Blood Volume: 140 Page(s): 1086 - 1093
    09/08/2022 Authors: Parekh A; Keller FG; McCarten KM; Kessel S; Cho S; Pei Q; Wu Y; Castellino SM; Constine LS; Schwartz CL
  • Case Report: The First Case Report of Visceral Leishmaniasis in Cambodia.
    Am J Trop Med Hyg Volume: 107 Page(s): 336 - 338
    08/17/2022 Authors: Lyvannak S; Sreynich K; Heng S; Thyl M; Chandna A; Chanpheaktra N; Pises N; Farrilend P; Jarzembowski J; Leventaki V
  • Pyrites: Proptosis.
    J Pediatr Hematol Oncol Volume: 44 Page(s): 347 - 350
    08/01/2022 Authors: Lyvannak S; Khauv P; Keller FG; Leventaki V; Camitta B
  • REMISSION OF AML IN A PATIENT WITH GERMLINE TP53 MUTATION AFTER DECITABINE MONOTHERAPY
    Volume: 69
    06/01/2022 Authors: Sadanand A; Qayed M; Keller F
  • Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation.
    Blood Adv Volume: 6 Page(s): 3058 - 3061
    05/24/2022 Authors: Janardan S; Horwitz E; Watkins B; Williams K; Chandrakasan S; Qayed M; Parikh S; Arnold S; Keller F; Alazraki A
  • Pyrites: A Lip Mass.
    J Pediatr Hematol Oncol Volume: 44 Page(s): 113 - 114
    04/01/2022 Authors: Lyvannak S; Sreynich K; Heng S; Farrilend P; Keller F; Tarlock K; Leventaki V; Camitta B
  • Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma.
    Int J Part Ther Volume: 8 Page(s): 55 - 57
    01/01/2022 Authors: Mailhot Vega RB; Castellino SM; Pei Q; Parsons S; Roberts KB; Hodgson D; Charpentier A-M; Fitzgerald TJ; Kessel SK; Keller FG
  • Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
    Lancet Haematol Volume: 9 Page(s): e49 - e57
    01/01/2022 Authors: Kahn JM; Pei Q; Friedman DL; Kaplan J; Keller FG; Hodgson D; Wu Y; Appel BE; Bhatia S; Henderson TO
  • Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
    Blood Adv Volume: 5 Page(s): 5519 - 5524
    12/28/2021 Authors: Forlenza CJ; Gulati N; Mauguen A; Absalon MJ; Castellino SM; Franklin A; Keller FG; Shukla N
  • USE OF HYPOMETHYLATING AGENTS IN RELAPSED/REFRACTORY PEDIATRIC ACUTE MYELOID LEUKEMIA
    Volume: 68 Page(s): S52 - S53
    06/01/2021 Authors: Sabnis H; Raikar S; Bennett A; MacDonald K; Watkins B; Woods W; Keller F
  • HSCT RESCUES MARROW FAILURE IN A PATIENT WITH LEUKEMIA AND PREVIOUSLY UNDIAGNOSED LIGASE IV SYNDROME
    Volume: 68 Page(s): S198 - S199
    06/01/2021 Authors: Fridlyand DM; Chandrakasan S; Aljudi A; Aumann W; Westfall E; Kirwan B; Bryson EW; Keller FG; Arnold SD; Hong AL
  • HSCT RESCUES MARROW FAILURE IN A PATIENT WITH LEUKEMIA AND PREVIOUSLY UNDIAGNOSED LIGASE IV SYNDROME
    Volume: 68 Page(s): S184 - S185
    06/01/2021 Authors: Fridlyand D; Chandrakasan S; Aljudi A; Aumann W; Westfall E; Kirwan B; Bryson E; Keller F; Arnold S; Hong A
  • CHARACTERISTICS AND OUTCOMES OF PEDIATRIC ONCOLOGY PATIENTS AT RISK FOR TRANSFUSION REFUSAL
    Volume: 68 Page(s): S97 - S98
    06/01/2021 Authors: Stevenson J; DeGroote N; Choudhury T; Keller F; Brock K; Bergsagel DJ; Miller T; Cornwell P; Chonat S; Castellino S
  • Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia.
    Pediatr Blood Cancer Volume: 67 Page(s): e28570
    11/01/2020 Authors: Shinn K; Wetzel M; DeGroote NP; Keller F; Briones M; Felker J; Castellino S; Miller TP
  • A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Leuk Res Volume: 96 Page(s): 106421
    09/01/2020 Authors: Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
  • Very late recurrence of B-cell acute lymphoblastic leukemia masquerading as a pituitary tumor.
    Pediatr Hematol Oncol Volume: 37 Page(s): 438 - 444
    08/01/2020 Authors: Fridlyand DM; Keller FG; Sabnis HS; Patterson BC; Gadde JA; Peragallo JH; Biousse V; Wechsler DS
  • Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A report from the Children's Oncology Group
    Volume: 29
    06/01/2020 Authors: Kahn J; Kelly KM; Pei Q; Bush R; Friedman DL; Keller FG; Bhatia S; Henderson TO; Schwartz CL; Castellino SM
  • The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).
    Volume: 38
    05/20/2020 Authors: Parsons SK; Rodday AM; Scharman C; Andre M; Federico M; Friedberg JW; Friedman DL; Gallamini A; Hay AE; Hoskin P
  • Experience with ponatinib in paediatric patients with leukaemia.
    Br J Haematol Volume: 189 Page(s): 363 - 368
    04/01/2020 Authors: Rossoff J; Huynh V; Rau RE; Macy ME; Sulis ML; Schultz KR; Burke MJ; Athale U; O'Brien MM; Gregory JJ
  • Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
    Volume: 232 Page(s): 83 - 83
    03/01/2020 Authors: Mauz-Koerholz C; Kelly KM; Keller FG; Ramchandren R; Nahar A; Giulino-Roth L
  • Impact of central review of imaging in an FDG-PET response adapted Pediatric Hodgkin lymphoma protocol
    Volume: 232 Page(s): 111 - 111
    03/01/2020 Authors: Hoppe BS; Castellino SM; Kessel S; Alazraki A; Voss S; Mhlanga J; Lai H; Eutsler E; Keller FG; Kelly KM
  • Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA)
    Volume: 232 Page(s): 108 - 108
    03/01/2020 Authors: Vega CMRB; Hoppe BS; Hodgson D; Charpentier AM; Fitzgerald TJ; Kessel S; Pei Q; Keller FG; Parsons SK; Kelly KM
  • Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children's Oncology Group trials
    Volume: 232 Page(s): 112 - 112
    03/01/2020 Authors: Kahn JM; Kelly KM; Pei Q; Friedman DL; Keller FG; Bhatia S; Henderson TO; Schwartz CL; Castellino SM
  • Assessment of tumor antigen specific T cell immunity and cytokine milieu at diagnosis in patients with high risk Hodgkin Lymphoma treated on Children's Oncology Group trial AHOD1331
    Volume: 232 Page(s): 87 - 87
    03/01/2020 Authors: Dave H; Horton TM; Mai M; Saunders D; Jenkins G; Pei Q; Keller FG; Castellino SM; Kelly KM; Bollard C
  • A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children's Oncology Group (COG) AHOD1331
    Volume: 232 Page(s): 82 - 83
    03/01/2020 Authors: Castellino SM; Parsons SK; Pei Q; McCarten K; Kessel S; Punnett A; Horton TM; Henderson TO; Hodgson D; Dave H
  • Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.
    Pediatr Blood Cancer Volume: 66 Page(s): e27975
    12/01/2019 Authors: Miller LH; Keller F; Mertens A; Klein M; Allen K; Castellino S; Woods WG
  • Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.
    J Clin Oncol Volume: 37 Page(s): 3009 - 3017
    11/10/2019 Authors: Kahn JM; Kelly KM; Pei Q; Bush R; Friedman DL; Keller FG; Bhatia S; Henderson TO; Schwartz CL; Castellino SM
  • The association of age, literacy, and race on completing patient-reported outcome measures in pediatric oncology.
    Qual Life Res Volume: 28 Page(s): 1793 - 1801
    07/01/2019 Authors: Withycombe JS; McFatrich M; Pinheiro L; Hinds PS; Keller FG; Baker JN; Mack JW; Sung L; Waldron MK; Reeve BB
  • CLINICAL VALUE OF RESPIRATORY VIRAL PANEL IN PEDIATRIC PATIENTS WITH CANCER AND FEBRILE NEUTROPENIA
    Volume: 66
    06/01/2019 Authors: Shinn K; Wetzel M; Keller F; Briones M; Felker J; Miller T
  • Phase 2, open-label study of pembrolizumab in children and young adults with newlydiagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
    Volume: 37
    05/20/2019 Authors: Mauz-Korholz C; Kelly KM; Keller FG; Ramchandren R; Nahar A; Giulino-Roth L
  • Evaluating approaches to enhance survival in children with hypodiploid acute lymphoblastic leukaemia (ALL).
    Br J Haematol Volume: 185 Page(s): 613 - 616
    05/01/2019 Authors: Miller L; Kobayashi S; Pauly M; Lew G; Saxe D; Keller F; Qayed M; Castellino S
  • Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States.
    Br J Haematol Volume: 183 Page(s): 385 - 399
    11/01/2018 Authors: Blum KA; Keller FG; Castellino S; Phan A; Flowers CR
  • Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
    Cancer Volume: 124 Page(s): 3210 - 3219
    08/01/2018 Authors: Keller FG; Castellino SM; Chen L; Pei Q; Voss SD; McCarten KM; Senn SL; Buxton AB; Bush R; Constine LS
  • Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
    Br J Haematol Volume: 182 Page(s): 212 - 221
    07/01/2018 Authors: Parsons SK; Kelly MJ; Cohen JT; Castellino SM; Henderson TO; Kelly KM; Keller FG; Henzer TJ; Kumar AJ; Johnson P
  • INCIDENCE AND PREDICTORS OF RESPIRATORY ADVERSE EVENTS DURING INDUCTION THERAPY IN CHILDREN WITH ACUTE MYELOID LEUKEMIA
    Volume: 65
    06/01/2018 Authors: Miller L; Castellino S; Mertens A; Keller F; Woods W
  • CHANGING BLOOD CULTURE STRATEGY: A QUALITY IMPROVEMENT PROJECT TO ELIMINATE THE PRACTICE OF AUTOMATIC DAILY BLOOD CULTURES IN HOSPITALIZED PEDIATRIC PATIENTS WITH FEVER AND NEUTROPENIA
    Volume: 65
    06/01/2018 Authors: Newton JG; Carter A; Head C; Leahy S; Olson T; Keller F; Wasilewski-Masker K
  • CHOLELITHIASIS IN PATIENTS WITH CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE SERIES
    Volume: 65
    06/01/2018 Authors: Cho S; Keller F
  • HEPATOTOXICITY REQUIRING LIVER BIOPSY IN CHILDREN WILL ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE SERIES
    Volume: 65
    06/01/2018 Authors: Yarnall N; Effinger K; Keller F
  • OUTCOMES WITHIN FIVE YEARS FROM THERAPY COMPLETION IN PEDIATRIC HODGKIN LYMPHOMA PATIENTS FOLLOWING CONTEMPORARY THERAPY
    PEDIATRIC BLOOD & CANCER Volume: 65
    06/01/2018 Authors: Effinger K; Keller F; Bergsagel J; Lawrence T; Lewis RW; Meacham L; Mertens A; Castellino S
  • ALLOPURINOL USE WITH 6-MERCAPTOPURINE IN MAINTENANCE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE SERIES
    PEDIATRIC BLOOD & CANCER Volume: 65
    06/01/2018 Authors: Phillips L; Minson K; Castellino S; Bergsagel J; Lew G; Sabnis H; Pauly M; Keller F
  • KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
    Volume: 36
    05/20/2018 Authors: Mauz-Korholz C; Kelly KM; Keller FG; Giulino-Roth L; Nahar A; Balakumaran A
  • Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
    Blood Volume: 131 Page(s): 573 - 577
    02/01/2018 Authors: Raikar SS; Park SI; Leong T; Jaye DL; Keller FG; Horan JT; Woods WG
  • Hemophagocytic Lymphohistiocytosis Secondary to T Cell/Histiocyte-rich Large B Cell Lymphoma in an Adolescent Male.
    Pediatr Dev Pathol Volume: 21 Page(s): 95 - 99
    01/01/2018 Authors: Metts JL; Park SI; Briones MA; Keller FG
  • Incidence and Predictors of Adverse Respiratory Events during Induction Therapy in Children with Acute Myeloid Leukemia
    Volume: 130
    12/07/2017 Authors: Miller L; Castellino SM; Mertens A; Keller FG; Woods WG
  • Isolated Myeloperoxidase Expression in Pediatric B/Myeloid Mixed Phenotype Acute Leukemia Is Associated with Improved Survival Using ALL-Only Regimens
    Volume: 130
    12/07/2017 Authors: Raikar SS; Park S; Leong T; Jaye DL; Keller FG; Horan JT; Woods WG
  • Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia
    BLOOD Volume: 130
    12/07/2017 Authors: Kumar S; Travers CD; Bergsagel J; Keller FG; Pauly M; Sabnis H; Castellino SM; Lew G
  • Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy
    BLOOD Volume: 130
    12/07/2017 Authors: Effinger KE; Bergsagel J; Lawrence T; Keller FG; Lewis RW; Meacham L; Mertens A; Castellino SM
  • Comment on: Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia.
    Pediatr Blood Cancer Volume: 65
    10/08/2017 Authors: Summers RJ; Metrock LK; Park S; Gillespie S; Castellino S; Lew G; Keller FG
  • Utility of peripheral blood immunophenotyping by flow cytometry in the diagnosis of pediatric acute leukemia.
    Pediatr Blood Cancer Volume: 64
    10/01/2017 Authors: Metrock LK; Summers RJ; Park S; Gillespie S; Castellino S; Lew G; Keller FG
  • Intensified induction therapy with reduced total anthracycline exposure in pediatric low-risk acute myeloid leukemia.
    Volume: 35
    05/20/2017 Authors: Minson KA; Herring C; Metts J; Sabnis H; Cooper TM; Woods WG; Keller FG
  • Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
    Pediatr Blood Cancer Volume: 64
    04/01/2017 Authors: Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA
  • A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia.
    Pediatr Blood Cancer Volume: 64
    04/01/2017 Authors: Mitchell SG; Bunting ST; Saxe D; Olson T; Keller FG
  • Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
    Volume: 128
    12/02/2016 Authors: Henderson TO; Castellino SM; Keller FG; Kelly KM; Curtis R; Conti RM; Parsons SK
  • APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS
    HAEMATOLOGICA Volume: 101 Page(s): 37 - 37
    10/01/2016 Authors: Castellino SM; Henderson TO; Keller F; Kelly K; Curtis R; Conti RM; Parsons SK
  • Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia.
    Pediatr Blood Cancer Volume: 63 Page(s): 1667 - 1670
    09/01/2016 Authors: Raikar SS; Scarborough JD; Sabnis H; Bergsagel J; Wu D; Cooper TM; Keller FG; Wood BL; Bunting ST
  • Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
    Pediatr Blood Cancer Volume: 63 Page(s): 712 - 715
    04/01/2016 Authors: Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
  • Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
    Pediatr Blood Cancer Volume: 62 Page(s): 2050 - 2051
    11/01/2015 Authors: Nickel RS; Daves M; Keller F
  • Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.
    Br J Haematol Volume: 169 Page(s): 647 - 660
    06/01/2015 Authors: Giulino-Roth L; Keller FG; Hodgson DC; Kelly KM
  • CORRELATION BETWEEN BONE MARROW SPICULARITY AND MINIMAL RESIDUAL DISEASE AMONG CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    PEDIATRIC BLOOD & CANCER Volume: 62 Page(s): 86 - 86
    06/01/2015 Authors: Milhollin S; Keller F; Lew G; Park S
  • USE OF LEVOFLOXACIN PROPHYLAXIS TO REDUCE INFECTIONS IN PATIENTS WITH AML
    PEDIATRIC BLOOD & CANCER Volume: 62 Page(s): 21 - 21
    06/01/2015 Authors: Daves M; Keller F; Ferdiallah A
  • Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    N Engl J Med Volume: 371 Page(s): 1005 - 1015
    09/11/2014 Authors: Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang Y-L; Pei D; McCastlain K; Ding L; Lu C; Song G
  • Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Pediatr Blood Cancer Volume: 61 Page(s): 1232 - 1238
    07/01/2014 Authors: Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C
  • UTILITY OF PERIPHERAL BLOOD IMMUNOPHENOTYPING BY FLOW CYTOMETRY IN THE DIAGNOSIS OF PEDIATRIC LEUKEMIA
    Volume: 61 Page(s): S84 - S84
    05/01/2014 Authors: Summers R; Williamson L; Gillespie S; Park S; Lew G; Keller F
  • Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
    Pediatr Hematol Oncol Volume: 31 Page(s): 311 - 317
    05/01/2014 Authors: Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
  • Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
    Pediatr Blood Cancer Volume: 61 Page(s): 810 - 814
    05/01/2014 Authors: Nickel RS; Keller F; Bergsagel J; Cooper T; Daves M; Sabnis H; Lew G
  • Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.
    J Clin Oncol Volume: 32 Page(s): 647 - 653
    03/01/2014 Authors: Wang X; Liu W; Sun C-L; Armenian SH; Hakonarson H; Hageman L; Ding Y; Landier W; Blanco JG; Chen L
  • SAFETY OF ASPARAGINASE ERWINIA CHRYSANTHEMI IN A LARGE COMPASSIONATE-USE TRIAL; SUBANALYSIS OF NEWLY DIAGNOSED AND RELAPSING PATIENTS
    PEDIATRIC BLOOD & CANCER Volume: 60 Page(s): 62 - 62
    09/01/2013 Authors: Plourde PV; Jeha S; Hijiya N; Keller F; Rheingold SR; Dreyer Z; Dahl G; Mercedes T; Corn T
  • SAFETY OF ASPARAGINASE ERWINIA CHRYSANTHEMI IN A COMPASSIONATE-USE TRIAL: A SUBANALYSIS OF THE ADOLESCENT/YOUNG ADULT PATIENT POPULATION
    Volume: 98 Page(s): 269 - 269
    06/12/2013 Authors: Plourde P; Jeha S; Hijiya N; Keller F; Rheingold S; Dreyer Z; Dahl G; Mercedes T; Corn T
  • Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
    Pediatr Blood Cancer Volume: 60 Page(s): 972 - 978
    06/01/2013 Authors: Kelly KM; Hodgson D; Appel B; Chen L; Cole PD; Horton T; Keller FG; COG Hodgkin Lymphoma Committee
  • Hyaluronidase synthase 3 (HAS3) variant and anthracycline-related cardiomyopathy: A report from the Children's Oncology Group.
    Volume: 31
    05/20/2013 Authors: Sun C-L; Wang X; Liu W; Armenian S; Hankonarson H; Hageman L; Ding Y; Landier W; Keller FG; Neglia JP
  • Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient (Pt) population
    Volume: 31
    05/20/2013 Authors: Plourde PV; Jeha S; Hijiya N; Keller FG; Rheingold SR; Dreyer Z; Dahl GVH; Mercedes T; Corn T
  • The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma
    Volume: 118 Page(s): 1559 - 1559
    11/18/2011 Authors: Schwartz C; Chen L; Constine L; Wolden S; Keller FG; Kelly KM; Friedman DI
  • Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
    Int J Radiat Oncol Biol Phys Volume: 80 Page(s): 324 - 332
    06/01/2011 Authors: Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
  • CHILDREN AND ADOLESCENTS WITH LOW RISK HODGKIN LYMPHOMA (HL)
    PEDIATRIC BLOOD & CANCER Volume: 56 Page(s): 883 - 883
    05/01/2011 Authors: Castellino S; Keller F; Dunphy C; McCarten K; Thomson J; Voss S; Nachman J; Constine L; Chen L; Schwartz C
  • A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)
    Volume: 116 Page(s): 337 - 337
    11/19/2010 Authors: Keller FG; Nachman J; Constine L; Thomson J; McCarten KM; Chen L; Schwartz C
  • What is the best treatment for children with limited-stage Hodgkin lymphoma?
    Curr Hematol Malig Rep Volume: 4 Page(s): 129 - 135
    07/01/2009 Authors: Keller FG; Castellino SM; Nachman JB
  • Neisseria sicca/subflava bacteremia presenting as cutaneous nodules in an immunocompromised host.
    Pediatr Infect Dis J Volume: 28 Page(s): 661 - 663
    07/01/2009 Authors: Jung JJ; Vu DM; Clark B; Keller FG; Spearman P
  • Role of FDG-PET in definition of involved-field radiation therapy for pediatric patients with Hodgkin's lymphoma
    Volume: 72 Page(s): S78 - S78
    01/01/2008 Authors: Esiashvili N; Halkar R; Keller F; Robertson VL; Fox TH; Waller AF; Curran WJ; Marcus RB
  • Wolinella asparaginase as an immunologically distinct, efficacious, and potentially less toxic asparaginase for use in lymphoid malignancies
    Volume: 110 Page(s): 264A - 264A
    11/16/2007 Authors: Watt TC; Keller FG; Durden DL
  • Posttransplant lymphoproliferative disease: a case report and review for the general pediatrician.
    Clin Pediatr (Phila) Volume: 46 Page(s): 287 - 291
    05/01/2007 Authors: Kincaid CR; Nield LS; Moore RS; Keller FG
  • Posttransplant lymphoproliferative disease: A case report and review for the general pediatrician
    CLINICAL PEDIATRICS Volume: 46 Page(s): 287 - 291
    05/01/2007 Authors: Kincaid CR; Nield LS; Moore RS; Keller FG
  • Molecular characterization of an 11q interstitial deletion in a patient with the clinical features of Jacobsen syndrome.
    Am J Med Genet A Volume: 140 Page(s): 704 - 708
    04/01/2006 Authors: Wenger SL; Grossfeld PD; Siu BL; Coad JE; Keller FG; Hummel M
  • Dominantly inherited beta thalassaemia intermedia caused by a new single nucleotide deletion in exon 2 of the beta globin gene: Hb morgantown (beta91 CTG>CG).
    J Clin Pathol Volume: 58 Page(s): 1110 - 1112
    10/01/2005 Authors: Luo H-Y; Tang W; Eung SH; Coad JE; Canfield P; Keller F; Crowell EH; Steinberg MH; Chui DHK
  • Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
    J Clin Oncol Volume: 19 Page(s): 2293 - 2301
    04/15/2001 Authors: Evans WE; Hon YY; Bomgaars L; Coutre S; Holdsworth M; Janco R; Kalwinsky D; Keller F; Khatib Z; Margolin J
  • The use of heparinase to neutralize residual heparin in blood samples drawn through pediatric indwelling central venous catheters.
    J Pediatr Volume: 132 Page(s): 165 - 167
    01/01/1998 Authors: Keller FG; DeFazio J; Jencks F; Steiner M; Rogers J; Ritchey AK
  • An unusual histiocytic disorder responding to cyclosporine therapy: a case report.
    J Pediatr Hematol Oncol Volume: 20 Page(s): 338 - 341
    01/01/1998 Authors: Ogershok PR; Keller FG; Favara BE; Ritchey AK
  • A survey of pediatric malignancy in West Virginia.
    W V Med J Volume: 94 Page(s): 279 - 282
    01/01/1998 Authors: Keller FG; Starling KA; Martin J; Defazio J; Steiner ME; Ritchey AK
  • Curing children with leukemia in West Virginia.
    W V Med J Volume: 93 Page(s): 179 - 181
    01/01/1997 Authors: Ritchey AK; Starling KA; Keller FG; Martin J; Steiner ME; Defazio J
  • Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease.
    Med Pediatr Oncol Volume: 26 Page(s): 48 - 53
    01/01/1996 Authors: Winter SS; Howard TA; Ritchey AK; Keller FG; Ware RE
  • Thrombin-catalyzed activation of recombinant human factor V.
    Biochemistry Volume: 34 Page(s): 4118 - 4124
    03/28/1995 Authors: Keller FG; Ortel TL; Quinn-Allen MA; Kane WH
  • ELEVATED LEVELS OF TUMOR NECROSIS FACTOR-BETA, GAMMA-INTERFERON, AND IL-6 MESSENGER-RNA IN CASTLEMANS DISEASE
    BLOOD Volume: 84 Page(s): A650 - A650
    11/15/1994 Authors: WINTER SS; HOWARD TA; RITCHEY AK; KELLER FG; WARE RE
  • Disseminated histoplasmosis: a cause of infection-associated hemophagocytic syndrome.
    Am J Pediatr Hematol Oncol Volume: 16 Page(s): 368 - 371
    11/01/1994 Authors: Keller FG; Kurtzberg J
  • Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.
    J Biol Chem Volume: 269 Page(s): 15898 - 15905
    06/03/1994 Authors: Ortel TL; Quinn-Allen MA; Keller FG; Peterson JA; Larocca D; Kane WH
  • Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.
    Am J Hematol Volume: 45 Page(s): 128 - 135
    02/01/1994 Authors: Ortel TL; Charles LA; Keller FG; Marcom PK; Oldham HN; Kane WH; Macik BG
  • FUNCTIONAL-CHARACTERIZATION OF THROMBIN CLEAVAGE SITES IN HUMAN COAGULATION FACTOR-V USING SITE-DIRECTED-MUTAGENESIS
    BLOOD Volume: 82 Page(s): A338 - A338
    11/15/1993 Authors: KELLER FG; ORTEL TL; QUINNALLEN MA; KANE WH
  • A FACTOR-V FACTOR-VIII LIGHT-CHAIN CHIMERA THAT EXPRESSES FACTOR-V PROCOAGULANT ACTIVITY AND IS RESISTANT TO NEUTRALIZATION BY A FACTOR-V INHIBITOR
    THROMBOSIS AND HAEMOSTASIS Volume: 69 Page(s): 1046 - 1046
    06/30/1993 Authors: ORTEL TL; QUINNALLEN MA; KELLER FG; KANE WH
  • EXPRESSION OF A SINGLE-CHAIN COAGULATION FACTOR-V DELETION MUTANT THAT POSSESSES CONSTITUTIVE PROCOAGULANT ACTIVITY
    CIRCULATION Volume: 86 Page(s): 686 - 686
    10/01/1992 Authors: ORTEL TL; QUINNALLEN MA; KELLER FG; KANE WH
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements